New combo shot CagriSema takes on childhood diabetes

NCT ID NCT07282613

Not yet recruiting Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jan 10, 2026 · Last updated Jun 23, 2026 · Updated 26 times

Summary

This study tests a once-weekly injection called CagriSema (a mix of cagrilintide and semaglutide) in 80 children and adolescents with type 2 diabetes. The goal is to see if it lowers blood sugar and body weight better than a placebo. The trial lasts about 15 months, with everyone getting CagriSema in the second part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

All India Institute of Medical Sciences (AIIMS)

New Delhi, 110029, India
Amir Ali Hassan, MD, PA

Houston, Texas, 77089, United States
BAPS Pramukh Swami Hospital

Surat, Gujarat, 395009, India
Carmel MC - Pediatric Endocrinology Unit

Haifa, 3436212, Israel
Centro de Diabetes Curitiba

Curitiba, Paraná, 80810-040, Brazil
Centro de Investigaciones Metabólicas

Capital Federal, Buenos Aires, C1056ABI, Argentina
Centro de Investigación C.I.C.E 9 de Julio - Sanatorio 9 de Julio

San Miguel de Tucumán, Tucumán Province, T4000DPX, Argentina
Centro de Investigación y Control Metabólico S. C.

San Nicolás de los Garza, Nuevo León, 66465, Mexico
Children's Hosptl Philadelphia

Philadelphia, Pennsylvania, 19104, United States
Clinical Research Trials of Florida

Tampa, Florida, 33607, United States
Clínica Mayo de Urgencias Médicas Cruz Blanca

San Miguel de Tucumán, T4000IHE, Argentina
Columbus Research Foundation

Columbus, Georgia, 31904, United States
Consano Clinical Research, LLC

Shavano Park, Texas, 78231, United States
Consultorio de Endocrinología y Pediatría

Puebla City, 72190, Mexico
D&H National Research Centers

Tamarac, Florida, 33321, United States
Eastside Bariatric and Gen Surg

Snellville, Georgia, 30078, United States
Encore Medical Research Boynton Beach

Boynton Beach, Florida, 33436, United States
Endolife Specialty Hospitals

Guntur, Andhra Pradesh, 522001, India
Excel Endocrine Centre

Kolhāpur, 416008, India
Fundacion Valle del Lili

Cali, Valle del Cauca Department, 760032, Colombia
Great Lakes Research Inst.

Southfield, Michigan, 48075, United States
HaEmek MC - Pediatric Endocrinology department

Afula, 1834111, Israel
Hospital Putrajaya

Putrajaya, 62250, Malaysia
Hospital Universitário Walter Cantídio

Bairro Rodolfo Teófilo, Fortaleza, Ceará, 60416-000, Brazil
IBTED Tecnologia e Educação em Diabetes - EPP

São Paulo, São Paulo, 04038-032, Brazil
IECSI Centro de Investigación Clínica

Monterrey, Nuevo León, 64310, Mexico
IMOBA

City of Buenos Aires, C1056ABH, Argentina
Indira Gandhi Institute of child health

Bangalore, Karnataka, 560011, India
Innovus Clinical

Kissimmee, Florida, 34741, United States
Institute of Child Health

Kolkata, West Bengal, 700017, India
Instituto Nacional de Pediatría

Coyoacán, Mexico City, 04530, Mexico
Instituto da Criança com Diabetes - ICD

Porto Alegre, Rio Grande do Sul, 91350-250, Brazil
Instituto da Criança e do Adolescente do HCFMUSP

São Paulo, São Paulo, 05403-000, Brazil
King Chulalongkorn Memorial Hospital

Bangkok, 10330, Thailand
LifeDoc Health

Memphis, Tennessee, 38115, United States
Maharaj Nakorn Chiang Mai Hospital_Pediatric Endocrinology

Chiang Mai, 50200, Thailand
Maulana Azad Medical College

Delhi, New Delhi, 110002, India
Monument Health Clinical Rsrch

Rapid City, South Dakota, 57701, United States
NYU Langone Orthopedic Center

New York, New York, 10016, United States
Nemours Chld Clnc Jacksonville

Jacksonville, Florida, 32207, United States
Rambam MC - Department of Pediatrics A

Haifa, 31096, Israel
Regency Hospital

Kanpur, Uttar Pradesh, 208006, India
Riley Hospital For Children

Indianapolis, Indiana, 46202, United States
SIU Medicine

Springfield, Illinois, 62702, United States
Salud SURA Industriales

Bogotá, Antioquia, 50017, Colombia
Seattle Children's Research Institute

Seattle, Washington, 98105, United States
Shaare Zedek MC - Pediatric Endocrinology

Jerusalem, 9103102, Israel
Sir Ganga Ram Hospital

New Delhi, National Capital Territory of Delhi, 110060, India
Soroka MC - Pediatric Endocrinology

Beersheba, 84101, Israel
Taipei Mackay Children's Hospital

Taipei, 104, Taiwan
UBMD Pediatrics

Buffalo, New York, 14203, United States
UVA Health Systems

Charlottesville, Virginia, 22903, United States
Unidade de Pesquisa Clínica do Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo

Ribeirão Preto, São Paulo, 14051-140, Brazil
University Malaya Medical Centre

Lembah Pantai, Kuala Lumpur, 59100, Malaysia
University of Iowa

Iowa City, Iowa, 52242, United States
Yale School of Medicine

New Haven, Connecticut, 06511, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

CagriSema (cagrilintide and semaglutide)

What this could lead to

If it works, this could offer a new treatment option to help children and teens with type 2 diabetes better control their blood sugar and weight.

What could go wrong

This is a Phase 3 trial, but it's small (80 participants) and results may not apply to all children. Side effects from the drugs are possible, and the placebo-controlled phase means some kids won't get the active treatment initially.

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS TYPE 2